system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Animals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Docetaxel, Doxorubicin, Drug Administration Schedule, Drug Synergism, Female, Humans, Inhibitory Concentration 50, Mammary Neoplasms, Experimental, Mice, Mice, Nude, Paclitaxel, Taxoids, Tumor Cells, Cultured, Xenograft Model Antitumor Assays.
user
Does docetaxel enhance the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner? Context: Taxanes and anthracyclines are active against breast cancer. In this study we investigated the combined antitumor activity of these drugs, with particular regard to sequence-dependency. The combined antitumor activity of docetaxel and tetrahydropyranyladriamycin (THP) against two human breast cancer xenografts was assessed using an in vitro histoculture drug-response assay. The sequence-dependency of the combined cytotoxicity was evaluated by isobologram. A synergistic antitumor activity of combined docetaxel + THP was exhibited against the R-27 xenograft when docetaxel was given first or simultaneously with THP. However, this synergism was diminished when THP was used before docetaxel. While an additive effect of combined docetaxel + THP was observed against MX-1 xenograft when docetaxel was given first or simultaneously with THP, this effect was not marked using the THP/docetaxel sequence.
assistant
Docetaxel increased the antitumor activity of THP, but only when administered before or simultaneously with THP. Final Decision: yes